Headquartered in Seattle, WA Fiscal year ends December NASDAQ: SANA sana.com
Sana Biotechnology is a clinical-stage biotechnology company that develops engineered cells as medicines and currently generates no product revenue. It has two core technology platforms.
- **Hypoimmune (HIP) gene modification:** designed to let transplanted allogeneic cells evade immune detection without immunosuppression. The lead program is SC451, an O-negative, HIP-modified, iPSC-derived pancreatic islet cell therapy intended as a one-time treatment for type 1 diabetes. It is supported by investigator-sponsored data from UP421, a HIP-modified primary islet cell therapy, and by a strategic collaboration with Mayo Clinic.
- **Fusosome (fusogen) in vivo delivery:** CD8-targeted particles that deliver genetic material to T cells to generate CAR T cells inside the body, without lymphodepleting chemotherapy. Programs include SG293 (CD19-directed, for non-Hodgkin lymphoma and potentially B cell-mediated autoimmune diseases) and SG227 (BCMA-directed, for multiple myeloma).
Sana relies on third-party contract development and manufacturing organizations (CDMOs) for manufacturing after suspending its internal manufacturing build-out in 2025. It also suspended its allogeneic CAR T programs. The company has contingent obligations to Cobalt Biomedicine (amended in August 2026) and Harvard tied to development milestones, business development transactions and market capitalization. It funds operations through equity financings and operates in Seattle, Cambridge and South San Francisco. Updated
A beneficial owner stepped up and took a controlling stake in a struggling retailer, while public offerings of stock prompted insider buying at some biotech companies.
Sana Biotechnology is a clinical-stage biotechnology company that develops engineered cells as medicines and currently generates no product revenue.
The Wall Street consensus 12-month price target for SANA is $8.43.
